Trial Profile
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2014
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Erdheim-Chester disease
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2014 New trial record